Skip to content

Comparison of therapeutic effects of prednisolone, acyclovir, and combination of these drugs in Bell´s Palsy

Comparison of therapeutic effects of prednisolone, acyclovir, and combination of these drugs in Bell´s Palsy

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT201109187575N1
Enrollment
180
Registered
2011-11-20
Start date
2010-05-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bell's palsy. Facial palsy

Interventions

Intervention 1: prednisone, a dose of 1 mg/kg body weight was given daily for 3 days. The treatment was tapered over the next 12 days. Intervention 2: Acyclovir, 400 mg every 5 hours per day for 10 da
Treatment - Drugs
prednisone, a dose of 1 mg/kg body weight was given daily for 3 days. The treatment was tapered over the next 12 days
Acyclovir, 400 mg every 5 hours per day for 10 days
Prednisone, a dose of 1 mg/kg body weight was given daily for 3 days. The treatment was tapered over the next 12 days. Those taking acyclovir received 400 mg every 5 hours per day for 10 days

Sponsors

Arak University of Medical Sciences,Vice chancellor for research
Lead Sponsor

Eligibility

Sex/Gender
All
Age
10 Years to 149 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Patients with Bell´s palsy; Age over 10 years Exclusion Criteria: More than 7 days have passed since the onset of paralysis; Finding another cause for the paralysis

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
House-Brackmann score. Timepoint: Each 15 days. Method of measurement: Calculate House-Brackmann score.

Secondary

MeasureTime frame
Failure to treatment. Timepoint: The end of month 3. Method of measurement: No reduce of House-Brackmann score.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Alireza Rezaei Ashtiani

Arak University of Medical Sciences

dr.ashtiani@arakmu.ac.ir+98 86 1224 1411

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026